Three technologies. One goal.
Every patient with advanced non-small cell lung cancer (NSCLC) deserves a molecular test before they start therapy. ONCO X gives Indian oncologists three ways to get there — tissue or liquid biopsy, standard or ultra-fast, plus a first-line cancer resistance test.
PulmoSmart on Tissue Biopsy
An 11-gene NSCLC panel on FFPE tissue — covering the actionable targets an Indian oncologist actually treats on: EGFR, ALK, ROS1, BRAF, MET, KRAS, RET, HER2, NTRK1/2/3. Standard turnaround, standard hardware.
See the panel →PulmoSmart Prime for Tissue Biopsy
The same panel, redesigned for speed. Two-day turnaround from sample-in to report-out — so oncologists don't lose a fortnight before they can start the right targeted therapy.
See the workflow →LiquiSmart Lung
Ultra-sensitive ctDNA test from a simple blood draw — including a first-line cancer resistance test to detect the mutations that will fail today's therapy tomorrow. Ideal when tissue is exhausted, QNS, or the patient is too fragile for re-biopsy.
See LiquiSmart Lung →One indication, three real-world entry points.
A newly-diagnosed patient with adequate tissue and a week to spare needs a different test than a patient in progression whose biopsy is exhausted. And both are different from the patient whose oncologist wants to know — before starting therapy — which resistance mutation is going to cut this response short.
PulmoSmart, PulmoSmart Prime and LiquiSmart Lung together cover all three, so no NSCLC patient falls between the cracks.
Ready to order?
We'll ship kits, connect you to our scientific team, and walk your lab through onboarding — all within one business day.
Contact ONCO X